We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Pragma Bio Stock

Invest in or calculate the value of your shares in Pragma Bio or other pre-IPO companies through EquityZen's platform.

Get Started

Pragma Bio Stock (PRAB)

Pragma Bio is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune diseases.

About Pragma Bio Stock

Founded

2018

Headquarters

Millbrae, CA, US

Industries

Software, Data and Analytics, Science and Engineering

Pragma Bio is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

Pragma Bio Management

Leadership team at Pragma Bio

Co-Founder & CEO

Kareem Barghouti

Co-Founder

Ayin Vala

Locked Features

Join now and verify your accreditation status to gain access to:

  • Pragma Bio current valuation
  • Pragma Bio stock price
  • Available deals in Pragma Bio and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Pragma Bio stock?

Accredited investors can buy pre-IPO stock in companies like Pragma Bio through EquityZen funds. These investments are made available by existing Pragma Bio shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Pragma Bio stock?

Shareholders can sell their Pragma Bio stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."